Ghasemi Asghar, Jeddi Sajad, Kashfi Khosrow
Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Biochem Pharmacol. 2025 Feb;232:116728. doi: 10.1016/j.bcp.2024.116728. Epub 2024 Dec 19.
One possible reason for failure in achieving optimal glycemic control in patients with type 2 diabetes (T2D) is that less attention has been paid to the brain, a fundamental player in glucose homeostasis, that consumes about 25% of total glucose utilization. In addition, animal and human studies indicate that nitric oxide (NO) is a critical player in glucose metabolism. NO synthesis from L-arginine is lower in patients with T2D, and endothelial NO synthase (eNOS)-derived NO bioavailability is lower in T2D. NO in the nervous system plays a role in neurovascular coupling (NVC) and the hypothalamic control of glucose sensing and energy homeostasis, influencing glucose utilization. This review explores NO's role in the brain's glucose metabolism. Literature indicates that glucose metabolism is different between neurons and astrocytes. Unlike neurons, astrocytes have a higher rate of glycolysis and a greater ability for lactate production. Astrocytes produce a greater amount of NO than neurons. NO inhibits mitochondrial respiration in both neurons and astrocytes and decreases intracellular ATP. NO-induced inhibition of mitochondrial respiration in neurons is not accompanied by compensatory glycolysis because phosphofructokinase 2.3 (PFK2.3), the most potent activator of PFK1 and thus glycolysis, is subjected to ubiquitylation and proteasomal degradation by cadherin-1 (Cdh1)-activated anaphase-promoting complex/cyclosome (APC/C), which leads to a low glycolytic rate in neurons. In astrocytes, NO inhibits mitochondrial respiration, but astrocytes display compensatory glycolysis by activating the adenosine monophosphate (AMP)-activated protein kinase (AMPK) pathway.
2型糖尿病(T2D)患者血糖控制未能达到最佳水平的一个可能原因是,作为葡萄糖稳态的关键参与者,大脑消耗了约25%的总葡萄糖利用率,但却较少受到关注。此外,动物和人体研究表明,一氧化氮(NO)是葡萄糖代谢的关键参与者。T2D患者中由L-精氨酸合成NO的水平较低,且T2D患者中内皮型一氧化氮合酶(eNOS)衍生的NO生物利用度较低。神经系统中的NO在神经血管耦合(NVC)以及下丘脑对葡萄糖感知和能量稳态的控制中发挥作用,影响葡萄糖利用。本综述探讨了NO在大脑葡萄糖代谢中的作用。文献表明,神经元和星形胶质细胞的葡萄糖代谢存在差异。与神经元不同,星形胶质细胞的糖酵解速率更高,产生乳酸的能力更强。星形胶质细胞产生的NO比神经元更多。NO抑制神经元和星形胶质细胞中的线粒体呼吸,并降低细胞内ATP水平。NO诱导的神经元线粒体呼吸抑制并未伴随糖酵解的代偿性增加,因为磷酸果糖激酶2.3(PFK2.3)作为PFK1以及糖酵解的最有效激活剂,会被钙黏蛋白-1(Cdh1)激活的后期促进复合物/细胞周期体(APC/C)进行泛素化和蛋白酶体降解,这导致神经元中的糖酵解速率较低。在星形胶质细胞中,NO抑制线粒体呼吸,但星形胶质细胞通过激活单磷酸腺苷(AMP)激活的蛋白激酶(AMPK)途径来进行糖酵解代偿。